Maximize your media exposure with our single PR package
Applied DNA enters FY2019 with strong momentum
25 Oct 18 2 min read
Applied DNA Sciences, the leader in large-scale PCR-based DNA manufacturing, has entered its FY2019 with strong momentum in the first month in textiles, food-based agriculture, and through the LineaRx subsidiary. The company is a provider of molecular technologies that enable supply chain security, anti-counterfeiting, and anti-theft technology.
Textiles business expansion includes a shipment of taggant for the upland Delta cotton variety in the current 2018-2019 ginning season, two new pilots for the company’s CertainT system in synthetic textiles (following one additional customer pilot completed in September 2018) and one new feasibility study for the tagging of a food-based agricultural commodity. LineaRx, the company’s wholly-owned subsidiary focused on next-generation biotherapeutics, received a new order for PCR-produced DNA for biotherapeutic applications, Applied DNA said in a media statement.
“Our structure for managing people, processes, and technologies supporting global cotton supply chains, from the US and Australian cotton gins, to local customer sales and support in India and Europe, through to our testing labs in Stony Brook and Ahmedabad, India and our partnerships with IT platform companies, has been a necessary investment for our unique selling proposition in end-to-end supply chain traceability. This sets a foundation from which our other supply chain pilots can be initiated and completed more quickly,” James Hayward, president and CEO of Applied DNA said.
“Our LineaRx opportunity looks strong, with steady inquiries incoming for DNA biotherapeutic products as the benefits of linear, PCR-produced DNA is highlighted in the media,” Hayward added. (GK)
Disclaimer - All News/Articles items are subject to copyright and no article either in full or part may be reproduced in any form without permission from Fibre2Fashion Pvt. Ltd.
Textiles business expansion includes a shipment of taggant for the upland Delta cotton variety in the current 2018-2019 ginning season, two new pilots for the company’s CertainT system in synthetic textiles (following one additional customer pilot completed in September 2018) and one new feasibility study for the tagging of a food-based agricultural commodity. LineaRx, the company’s wholly-owned subsidiary focused on next-generation biotherapeutics, received a new order for PCR-produced DNA for biotherapeutic applications, Applied DNA said in a media statement.
“Our structure for managing people, processes, and technologies supporting global cotton supply chains, from the US and Australian cotton gins, to local customer sales and support in India and Europe, through to our testing labs in Stony Brook and Ahmedabad, India and our partnerships with IT platform companies, has been a necessary investment for our unique selling proposition in end-to-end supply chain traceability. This sets a foundation from which our other supply chain pilots can be initiated and completed more quickly,” James Hayward, president and CEO of Applied DNA said.
“Our LineaRx opportunity looks strong, with steady inquiries incoming for DNA biotherapeutic products as the benefits of linear, PCR-produced DNA is highlighted in the media,” Hayward added. (GK)
Fibre2Fashion News Desk – India
Popular News
|
South Indian cotton yarn market bearish; steep fall in Mumbai |
|
China, Australia deliberate FTA execution: Reports |
|
KBR to license Phenol tech for SABIC's China project |
|
UK manufacturing sector sees improved sentiment in April: CBI |
|
Vietnam's silk exports to India reach $110 mn in 2023 |
|
Chinese firm to set up $27.8 mn sock manufacturing plant in Bangladesh |